International Assets Investment Management LLC Has $2.71 Million Stock Position in Progyny, Inc. (NASDAQ:PGNY)

International Assets Investment Management LLC decreased its holdings in shares of Progyny, Inc. (NASDAQ:PGNY) by 94.0% in the fourth quarter, Holdings Channel reports. The firm owned 152,964 shares of the company’s stock after selling 2,412,154 shares during the quarter. International Assets Investment Management LLC’s holdings in Progyny were worth $2,712,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Hsbc Holdings PLC increased its stake in shares of Progyny by 703.9% in the 2nd quarter. Hsbc Holdings PLC now owns 46,475 shares of the company’s stock valued at $1,328,000 after buying an additional 40,694 shares during the period. Kestrel Investment Management Corp bought a new stake in Progyny during the 2nd quarter worth about $5,005,000. Farallon Capital Management LLC lifted its position in Progyny by 120.8% during the 2nd quarter. Farallon Capital Management LLC now owns 1,308,500 shares of the company’s stock valued at $37,436,000 after purchasing an additional 715,900 shares during the period. Kornitzer Capital Management Inc. KS boosted its stake in shares of Progyny by 15.7% in the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 976,501 shares of the company’s stock valued at $16,366,000 after purchasing an additional 132,672 shares during the last quarter. Finally, Aurora Investment Counsel acquired a new stake in shares of Progyny during the 3rd quarter worth approximately $1,280,000. 94.93% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Progyny news, CEO Peter Anevski bought 209,500 shares of Progyny stock in a transaction on Monday, December 23rd. The shares were purchased at an average price of $14.48 per share, with a total value of $3,033,560.00. Following the acquisition, the chief executive officer now owns 441,463 shares in the company, valued at $6,392,384.24. This trade represents a 90.32 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman David J. Schlanger bought 150,000 shares of the firm’s stock in a transaction on Thursday, December 26th. The stock was acquired at an average price of $14.68 per share, for a total transaction of $2,202,000.00. Following the transaction, the chairman now owns 228,269 shares of the company’s stock, valued at approximately $3,350,988.92. The trade was a 191.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 12.30% of the company’s stock.

Progyny Price Performance

NASDAQ:PGNY traded up $0.33 on Wednesday, hitting $17.81. 146,402 shares of the company’s stock were exchanged, compared to its average volume of 1,505,512. Progyny, Inc. has a 52 week low of $13.39 and a 52 week high of $42.08. The company has a market cap of $1.52 billion, a P/E ratio of 30.71, a price-to-earnings-growth ratio of 1.64 and a beta of 1.31. The firm has a 50-day moving average price of $15.45 and a 200-day moving average price of $19.97.

Progyny (NASDAQ:PGNY) last released its quarterly earnings results on Tuesday, November 12th. The company reported $0.11 earnings per share for the quarter, missing the consensus estimate of $0.37 by ($0.26). The firm had revenue of $286.63 million for the quarter, compared to analyst estimates of $296.85 million. Progyny had a return on equity of 11.36% and a net margin of 5.03%. The business’s revenue for the quarter was up 2.0% on a year-over-year basis. During the same period in the previous year, the business posted $0.16 earnings per share. On average, research analysts expect that Progyny, Inc. will post 0.59 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Jefferies Financial Group reduced their price target on Progyny from $31.00 to $24.00 and set a “buy” rating on the stock in a research report on Thursday, September 19th. Leerink Partners decreased their target price on Progyny from $25.00 to $21.00 and set a “market perform” rating for the company in a research report on Thursday, September 19th. JMP Securities downgraded shares of Progyny from an “outperform” rating to a “market perform” rating in a research report on Thursday, September 19th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $25.00 target price on shares of Progyny in a research note on Tuesday, October 1st. Finally, Truist Financial reissued a “hold” rating and set a $19.00 price target (down from $26.00) on shares of Progyny in a research report on Wednesday, November 13th. Nine research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $25.00.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.